This shows you the differences between two versions of the page.
Both sides previous revision Previous revision Next revision | Previous revision Next revision Both sides next revision | ||
projects:workgroups:clinicalstudy [2019/03/01 16:27] sdolley |
projects:workgroups:clinicalstudy [2019/03/01 18:19] sdolley |
||
---|---|---|---|
Line 9: | Line 9: | ||
**Members:** | **Members:** | ||
* Andrew Williams, PhD, Tufts | * Andrew Williams, PhD, Tufts | ||
- | * Greg Klebanov, Odysseus | + | * Greg Klebanov, MS, Odysseus |
* Rupa Makadia, PhD, Janssen | * Rupa Makadia, PhD, Janssen | ||
* Vojtech Huser, PhD, NIH | * Vojtech Huser, PhD, NIH | ||
Line 18: | Line 18: | ||
* Ana Heredia, GMV | * Ana Heredia, GMV | ||
* Ayesha Kang, Deloitte | * Ayesha Kang, Deloitte | ||
- | * Kees van Bochove, The Hyve | + | * Kees van Bochove, MS, The Hyve |
- | * Maxim Moinat, The Hyve | + | * Maxim Moinat, MS, The Hyve |
* Sonia Araujo, PhD, IQVIA | * Sonia Araujo, PhD, IQVIA | ||
**Start Date:** 2019 (this started as 'Clinical Study' working group in 2016 and was dormant) | **Start Date:** 2019 (this started as 'Clinical Study' working group in 2016 and was dormant) | ||
- | **Repository:** To be organized soon. | + | **Repository:** |
+ | White paper on RWE in trials: | ||
+ | * {{:projects:workgroups:using-real-world-evidence-to-optimize-clinical-trials_2018-shyftanalytics.pdf|Using RWE in Trials by SHYFT Analytics}} | ||
</WRAP> | </WRAP> |